1Y Target$157.83Near-term target
5Y Target$216.39Compound horizon
10Y Target$318.08Long-dated conviction
FCF$10.2bTTM · 03/26A-FCF $10.2b — top-quartile, exceptional for any sector · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+4.4%TTM YoYC+Revenue +4.4% — steady but below market-beating range
D/E0.95BD/E 0.95 — at market average, manageable
P/E18.3xBP/E 18.3 — moderate premium, defensible with growth
PEG2.14CPEG 2.14 — expensive relative to growth rate
Why now
Drug Manufacturers - General · market cap $166.8b. 15% off the 52-week high of $157.29. 29 sell-side analysts rate this a Buy with a mean 1-yr target of $157.83 (implying +17% upside).
Moat
Net margin 31% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 43% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 111% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon
1-3 yr $157.83 (29-analyst consensus) — fundamentals + valuation re-rating. 5 yr $216.39 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $318.08 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.